C. Ola LandgrenPhD, MD
Sloan Kettering Institute for Cancer Research
Project Term: July 1, 2019 - June 30, 2020
The objective of this study is to prevent relapse by ruling out presence of last residual disease, and thereby facilitate the development of curative treatment strategies for multiple myeloma, which currently is viewed as an incurable disease.
To overcome the inherent dilemmas with blind bone marrow biopsies/aspirates and the limitations of blood-based protein markers, we have developed a targeted immuno-PET imaging to rule out minimal residual disease (MRD) in multiple myeloma and its precursor disease. Specifically, we have developed a PET tracer based upon daratumumab for tracking CD38 expression, which is an antigen consistently expressed by myeloma cells. We have already generated a murine xenograft model of the OPM2 cell line in our laboratory, allowing us to conduct further in vivo studies. Longitudinal PET imaging is being performed following injection of 5-10 MBq 89Zr-Df-daratumumab out to 120 h post-injection. Based on our preclinical results, we are now planning to develop a clinical protocol to develop this approach in patients with multiple myeloma and its precursor disease. This grant is intended to support the clinical development of our CD38-targeted immuno-PET imaging to rule out minimal residual disease (MRD) in multiple myeloma and its precursor disease.